BioSpace News Archive

Level I Randomized Clinical Trial Demonstrates Significantly Improved and Sustained Outcomes with 10 kHz Spinal Cord Stimulation Patients Suffering from Painful Diabetic Neuropathy Experienced Substantial, Sustained Pain Relief and Improved Health-Related Quality of Life

Advantech, a global leader of advanced IoT intelligence systems and embedded platforms, is pleased to announce the launch of its One-to-One Visitor Thermal Screening Kiosk, the cost effective version of its Visitor Thermal Screening System that was released in 2020.

This Nature Biomedical Engineering publication demonstrates that Cardea’s new CRISPR-powered transistors, dubbed “SNP-Chip,” has the power to enable a new generation of genetics testing that will democratize genetics by removing the need for a lab.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021, at 9:30 AM EDT.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021 .

Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced that it has entered into an agreement with East West Bank in which EWB will provide a $7.5 million working capital line of credit.

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.

ION363, the first medicine to specifically target FUS-ALS, is among Ionis’ wholly owned assets the company plans to commercialize